|
Video: What is a Stock Split?
|
|
Trillium Therapeutics is a clinical stage immuno-oncology company developing therapies for the treatment of cancer. Co.'s primary program, TTI-621, is a SIRPaFc fusion protein that consists of the extracellular CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the Fc region of a human immunoglobulin G1 (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Co. is also developing a second SIRPaFc fusion protein, TTI-622, which consists of the extracellular CD47-binding domain of human SIRPa linked to a human immunoglobulin G4 Fc region, which has a decreased ability to engage Fc receptors than an IgG1 Fc. According to our TRIL split history records, TRIL has had 1 split. | |
|
TRIL (TRIL) has 1 split in our TRIL split history database. The split for TRIL took place on November 20, 2014. This was a 1 for 30 reverse split, meaning for each 30 shares of TRIL owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as TRIL conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TRIL split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TRIL shares, starting with a $10,000 purchase of TRIL, presented on a split-history-adjusted basis factoring in the complete TRIL split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
11/17/2021 |
|
Start price/share: |
$10.41 |
|
End price/share: |
$18.44 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
77.14% |
|
Average Annual Total Return: |
7.85% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$17,708.19 |
|
Years: |
7.56 |
|
|
|
Date |
Ratio |
11/20/2014 | 1 for 30 |
|
|